文献速递心力衰竭与心肌病

酰基胃饥饿素改善射血分数降低心衰患者心输出量及心肌细胞收缩功能

Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization.
PubMed 文献 · Eur Heart J · 2023-01-01

一项随机安慰剂对照双盲试验纳入31例慢性射血分数降低心衰患者,静脉输注合成人酰基胃饥饿素(0.1 µg/kg/min)120分钟,主要终点心输出量显著增加(P<0.001),未引起低血压、心动过速、心律失常或心肌缺血。离体小鼠心肌细胞中酰基胃饥饿素增加缩短分数且不依赖钙动员,该效应可被拮抗剂阻断。

要点

  • 酰基胃饥饿素静脉输注可增加HFrEF患者心输出量,且不引起低血压或心律失常。
  • 离体心肌细胞中酰基胃饥饿素增强收缩力不依赖钙瞬变,可能解释临床安全性。
  • 酰基胃饥饿素对心输出量的改善作用需在更多随机试验中进一步验证。

核心结论

  • 在HFrEF患者中,酰基胃饥饿素增加心输出量且不引起低血压、心动过速、心律失常或心肌缺血。
  • 离体心肌细胞中酰基胃饥饿素增加收缩力且不依赖前负荷、后负荷及钙动员,可能解释临床副作用少。
  • 酰基胃饥饿素治疗值得在更多随机试验中探索。

研究设计与样本

  • 随机安慰剂对照双盲试验纳入31例慢性HFrEF患者,随机接受合成人酰基胃饥饿素(0.1 µg/kg/min)或安慰剂静脉输注120分钟。
  • 离体小鼠心肌细胞经酰基胃饥饿素处理,评估缩短分数与钙瞬变。

主要发现

  • 酰基胃饥饿素组心输出量从4.08 ± 1.15升至5.23 ± 1.98 L/min,安慰剂组从4.26 ± 1.23至4.11 ± 1.99 L/min,P < 0.001。
  • 酰基胃饥饿素显著增加每搏输出量,左室射血分数、节段纵向应变及三尖瓣环收缩期位移呈名义性增加。
  • 对血压、心律失常或心肌缺血无影响;心率呈名义性下降(酰基胃饥饿素组71 ± 11降至67 ± 11 b.p.m.;安慰剂组69 ± 8至68 ± 10 b.p.m.)。
  • 离体心肌细胞中酰基胃饥饿素增加缩短分数,不影响细胞钙瞬变,并降低肌钙蛋白I磷酸化。
  • 缩短分数增加及肌钙蛋白I磷酸化降低可被酰基胃饥饿素拮抗剂D-Lys 3阻断。

临床怎么用

  • 酰基胃饥饿素可能作为HFrEF患者增加心输出量而不引起低血压或心律失常的潜在治疗选择,但需更多随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Ghrelin is an endogenous appetite-stimulating peptide hormone with potential cardiovascular benefits. Effects of acylated (activated) ghrelin were assessed in patients with heart failure and reduced ejection fraction (HFrEF) and in ex vivo mouse cardiomyocytes. METHODS AND RESULTS: In a randomized placebo-controlled double-blind trial, 31 patients with chronic HFrEF were randomized to synthetic human acyl ghrelin (0.1 µg/kg/min) or placebo intravenously over 120 min. The primary outcome was change in cardiac output (CO). Isolated mouse cardiomyocytes were treated with acyl ghrelin and fractional shortening and calcium transients were assessed. Acyl ghrelin but not placebo increased cardiac output (acyl ghrelin: 4.08 ± 1.15 to 5.23 ± 1.98 L/min; placebo: 4.26 ± 1.23 to 4.11 ± 1.99 L/min, P < 0.001). Acyl ghrelin caused a significant increase in stroke volume and nominal increases in left ventricular ejection fraction and segmental longitudinal strain and tricuspid annular plane systolic excursion. There were no effects on blood pressure, arrhythmias, or ischaemia. Heart rate decreased nominally (acyl ghrelin: 71 ± 11 to 67 ± 11 b.p.m.; placebo 69 ± 8 to 68 ± 10 b.p.m.). In cardiomyocytes, acyl ghrelin increased fractional shortening, did not affect cellular Ca2+ transients, and reduced troponin I phosphorylation. The increase in fractional shortening and reduction in troponin I phosphorylation was blocked by the acyl ghrelin antagonist D-Lys 3. CONCLUSION: In patients with HFrEF, acyl ghrelin increased cardiac output without causing hypotension, tachycardia, arrhythmia, or ischaemia. In isolated cardiomyocytes, acyl ghrelin increased contractility independently of preload and afterload and without Ca2+ mobilization, which may explain the lack of clinical side effects. Ghrelin treatment should be explored in additional randomized trials. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05277415.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lund, Hage, Pironti, et al. Acyl ghrelin improves cardiac function in heart failure and increases fractional shortening in cardiomyocytes without calcium mobilization. Eur Heart J. 2023. PMID: 36916707. doi:10.1093/eurheartj/ehad100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。